Jitai Technology Begins Preparations for A-Share Listing as Commercialization of AI Drug Delivery Accelerates
Jitai Technology has begun preparations for an A-share listing and engaged a pre-listing advisory firm, but has yet to finalize a supporting plan or submit a formal application. Revenue in the first half of this year reached RMB 154 million, up 13,399% year on year, while its adjusted net loss narrowed by 56.4% to RMB 51 million. The company has also recently entered into partnerships with Eli Lilly, JOINN Laboratories and Hengrui Pharma to advance the commercialization of LNP and mRNA drugs and the AiTEM platform.
Topics
Body · AI translation
Following its debut on the Hong Kong Stock Exchange in May this year as the “world’s first listed AI drug delivery company,” METiS Technologies (07666.HK) announced after the market closed on November 18 that, to support business development and enhance its overall competitiveness, it has formally begun preparations for an A-share listing and appointed a pre-listing advisory institution. It will subsequently submit an application for advisory registration to regulators in accordance with applicable laws and regulations.
The announcement said that, as of its date, the company had not yet finalized other supporting plans for the A-share listing or submitted a formal listing application to domestic regulators. Subsequent plans will still be subject to internal decision-making and regulatory approval procedures and therefore remain uncertain.
METiS Technologies was co-founded in 2020 by U.S. National Academy of Engineering member Hongmin Chen, MIT scientist Caida Lai, and Wenshou Wang, and successfully listed on the Hong Kong Stock Exchange on May 13 this year.
In terms of fundamentals, METiS Technologies recorded revenue of RMB154 million in the first half of this year, up 13,399% year on year. Its adjusted net loss narrowed sharply by 56.4% to RMB51 million, while research and development expenses rose 48.1% year on year to RMB172 million. As of June 30, 2026, the company had cash reserves of RMB3.025 billion, while its debt-to-asset ratio improved from 19.3% at the end of 2025 to 9%, indicating ample liquidity and a sound financial structure.
On the commercialization front, METiS Technologies has recently entered into a series of strategic partnerships. On October 19, the company announced a strategic collaboration with Eli Lilly focused on researching and discovering novel lipid nanoparticle (LNP) delivery solutions aimed at enabling tissue-specific delivery of therapeutics. In September this year, METiS Technologies announced that it had formally signed a joint venture agreement with JOINN Biologics to establish Zhaotai Zhiyao, a joint venture that will develop an innovative R&D and commercial-scale manufacturing platform for mRNA drugs. In early August, it announced a partnership with Hengrui Pharma, under which its proprietary AiTEM AI-powered formulation innovation platform will be deployed locally at Hengrui Pharma to accelerate the development of drug formulations.
AI Trends